ZURA BIO LTD (ZURA:NASDAQ)
$5.23 -0.06 (-1.1342%)
Analysed ZURA BIO LTD (ZURA:NASDAQ) News Sources
Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress
29-11-2025
yahoo.com
December 2025's Top Penny Stocks With Promising Potential
15-12-2025
yahoo.com
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026
16-02-2026
marketbeat.com
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst
25-02-2026
fool.com
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
25-02-2026
fool.com
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
25-02-2026
fool.com
One Zura Bio Insider Raised Their Stake In The Previous Year
23-04-2026
yahoo.com
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation
03-06-2026
yahoo.com
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
29-06-2026
yahoo.com
William Blair Starts Zura Bio (ZURA) at Outperform
14-07-2026
yahoo.com
What is the current price of ZURA BIO LTD (ZURA:NASDAQ)?
The current price of ZURA BIO LTD (ZURA:NASDAQ) is $5.23.
ZURA BIO LTD (ZURA:NASDAQ) absolute price change since previous trading day?
The absolute price change of ZURA BIO LTD (ZURA:NASDAQ) since the previous trading day is $-0.06.
ZURA BIO LTD (ZURA:NASDAQ) percentage price change since previous trading day?
The percentage price change of ZURA BIO LTD (ZURA:NASDAQ) since the previous trading day is -1.1342%.
What is the most recent average sentiment score for ZURA BIO LTD (ZURA:NASDAQ)?
The most recent average sentiment score for ZURA BIO LTD (ZURA:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for ZURA BIO LTD (ZURA:NASDAQ)?
The most recent sentiment for ZURA BIO LTD (ZURA:NASDAQ) is .
SEC-8K** Filing Available For ZURA BIO LTD (ZURA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.